Vericel Q2 2025 Earnings Report

Vericel EPS Results

• Actual EPS: N/A
• Consensus EPS: -$0.04
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Vericel Revenue Results

• Actual Revenue: N/A
• Expected Revenue: $64.61 million
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Vericel Announcement Details

• Quarter: Q2 2025
• Date: 8/7/2025
• Time: Before Market Opens
• Conference Call Date: Thursday, July 31, 2025
• Conference Call Time: 8:30AM ET

Vericel (NASDAQ:VCEL) (NASDAQ: VCEL) is a commercial-stage biopharmaceutical company specializing in the development and marketing of advanced cell therapies for patients with serious diseases and conditions. The company focuses on harnessing the body’s natural repair mechanisms to restore tissue function, with a core emphasis on orthopedics and severe burn care. Vericel operates state-of-the-art manufacturing facilities that support the production of autologous cell therapy products under Good Manufacturing Practice (GMP) standards.

Vericel’s flagship products include MACI® (autologous cultured chondrocytes on porcine collagen membrane), approved by the U.S. Food and Drug Administration (FDA) for the repair of symptomatic cartilage defects of the knee, and Epicel® (cultured epidermal autografts), indicated for the treatment of deep dermal or full-thickness burns. These products represent some of the first commercially available, FDA-approved autologous cell therapies and have been implanted in thousands of patients since their respective approvals.

In addition to its marketed products, Vericel maintains a pipeline of investigational therapies aimed at expanding the applications of its cell technology platform. Clinical programs include next-generation approaches for orthopedic repair and vascular injury, leveraging proprietary cell processing and delivery methods. The company also explores collaborations and licensing opportunities to extend its geographic reach and address unmet medical needs in global markets.

Founded through the strategic acquisition of cell therapy assets and completing its initial public offering in 2012, Vericel is headquartered in Cambridge, Massachusetts, and operates additional facilities in North Carolina. The company’s leadership team is led by President and Chief Executive Officer Helen I. Torley, who brings extensive experience in biopharmaceutical operations and regenerative medicine. Vericel continues to invest in research, manufacturing scale-up, and commercial initiatives to advance the field of regenerative cell therapies.